BETHESDA, Md.--(BUSINESS WIRE)--Micromet, Inc. (NASDAQ: MITI) today announced the presentation of updated results from an on-going Phase 1 trial of the Company’s lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin’s lymphoma (NHL). Results of the expanded experience suggest that blinatumomab continues to produce a high response rate and duration of response in a number of different NHL subtypes. Among patients who received the target dose of 60 micrograms per meter squared, 82% (18 of 22) achieved an objective response, including 4 out of 5 mantle cell lymphoma (MCL) patients. Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body’s T cells to kill cancer cells.
